undamentalytics Newsletter
Sign in

Strata Critical Medical, Inc. (SRTA) stock

Add to watchlist

Add holding +

NASDAQ: SRTA Nasdaq Health Care Services Next results ~November 3, 2026

Strata Critical Medical, Inc. is a US-listed company in the health care services industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: data-quality checks not passed.

Price vs value

Under review: data-quality checks not passed. We'll show the comparison once resolved.

Strata Critical Medical, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders2 buying, 5 selling2 purchases and 10 sales by directors and officers, last 12 monthsInsider trades
  • Funds81 adding, 54 cuttingOf 28 active managers that changed their stake, 18 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Strata Critical Medical files

Where Strata Critical Medical stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $256m, up 66.8% on a year earlier, faster than the 29.6% growth a quarter earlier. Free-cash-flow margin fell to -19.3% from -12.7% a year earlier. Operating margin widened to -8.0% from -15.2%. The diluted share count is up 8.1% on a year earlier, which dilutes existing holders. It passes 2 of our 2 financial-health checks.

Our model value for Strata Critical Medical is under review, so past values are not shown until it is resolved.

Source: 10-Q filed August 4, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 3, 2026 (estimated)

Strata Critical Medical, Inc.'s trailing-twelve-month revenue grew 66.8% year on year, with a free-cash-flow margin of -19.3%.

Current signal Revenue growth accelerating: TTM revenue growth rose to 66.8% (+37.1pp vs the prior quarter).

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Fast growth. Revenue grew 66.8% over the last 12 months.
  • Growth speeding up. The growth rate is 37.1 points higher than a quarter earlier.
  • Margins widening. Operating margin is up 7.2 points on a year ago.

Things to watch

  • Loss-making. Operating margin is -8.0%: costs exceed revenue.
  • Burning cash. Free cash flow was -19.3% of revenue over the last 12 months.
  • Share dilution. Diluted shares rose 8.1% in a year.
  • Volatile shares. Over the past year the shares showed annualised volatility of 55% and a beta of 2.1 against the S&P 500.
  • Weak cash conversion. Free cash flow was -123% of net income over the last 12 months.
  • Missing expectations. Earnings per share fell short of the consensus estimate in 3 of the last four quarters.

Latest results: FY2026 Q2

Filed August 4, 2026
Earnings per share
-$0.12 against an average estimate of -$0.02: missed by 500.0%
Revenue
$73m, up 60.7% on a year earlier
Share reaction
+5.4% in the first session after the results on August 4, 2026, against +1.6% for the S&P 500
Next report
November 3, 2026

Strata Critical Medical's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-3.6%
  • 1 week-10.1%
  • 1 month-9.5%
  • This year-11.0%
  • 1 year-14.9%
  • 5 years-57.3%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$256M
Operating margin
-8.0%
Net margin
15.7%
EPS (TTM, diluted)
$0.47

Growth

Revenue growth
+66.8%
Change in growth rate
+37.1 pts
Share count change
+8.1%

Cash

Free cash flow (TTM)
-$49.5M
FCF margin
-19.3%
Stock pay % of revenue
6.6%

Earnings

Last results
November 3, 2026
Next results (est.)
February 1, 2027

News & updates

Updated November 3, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Results
  2. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Strata Critical Medical, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: data-quality checks not passed.

The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.

Valuation models

We value Strata Critical Medical, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 10%: the 10-year Treasury yield (4.9%) plus a beta of 1.12 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. — Does not apply: This model is withheld pending its input or assumption review.
Forward price-to-earnings vs peers Next year's consensus earnings per share times peers' typical (harmonic-mean) forward price-to-earnings. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$0.1 ~$0.1–$0.1 Left out: out of range vs price (0.01x)
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: This model is withheld pending its input or assumption review.
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: This model is withheld pending its input or assumption review.
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. — Does not apply: This model is withheld pending its input or assumption review.
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: This model is withheld pending its input or assumption review.
Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. — Combined value withheld. Review the individual models and their assumptions.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Strata Critical Medical, Inc. with Health Care Services in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 202020212022202320242025Now
Share price$10.05$10.40$3.58$3.53$4.25$4.81$4.28
Market value$253m$446m$255m$260m$329m$395m$368m
+ Net debt (− = net cash)$0$0−$41m−$28m−$18m−$31m−$16m
Enterprise value$253m$446m$214m$232m$311m$364m$351m
Multiples
Price / sales 10.8x8.8x1.7x1.2x2.2x2.0x1.4x
Price / earnings —————9.6x9.1x
Price / free cash flow ———————
EV / EBITDA ———————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

15 /100

Weak moat

How hard Strata Critical Medical's competitive advantage looks for rivals to wear away, judged from 7 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -7.4% of total assets over 7 years.

  • Pricing power 8 / 20

    Gross margin has been a median 18.6%, moving by 2.3 percentage points (standard deviation) across 5 years.

  • Durability 10 / 20

    Operating margin has been a median -28.2%; its worst year was -40.8%.

  • Cash conversion 0 / 20

    Free cash flow was positive in 0 of 6 years, at a median -20.7% of revenue.

  • Discipline 2 / 20

    The diluted share count rose 209.0% over five years; stock-based pay has been a median 8.5% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (20 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 3, 2026, before the open. Analysts expect revenue of $73m for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$0.09 +62% $291m +48%
Next $0.00 +104% $326m +12%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +131.3% on 90 days ago. In the last 30 days, 1 analyst raised Strata Critical Medical, Inc.'s forecast and 0 cut it.

Consensus EPS forecast Strata Critical Medical, Inc., last 90 days
−$0.10 −$0.05 $0.00 $0.05 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$0.04 Current fiscal year, 60 days ago: −$0.09 Current fiscal year, 30 days ago: −$0.09 Current fiscal year, 7 days ago: −$0.09 Current fiscal year, Now: −$0.09 −$0.09 Next fiscal year, 90 days ago: −$0.01 Next fiscal year, 60 days ago: $0.00 Next fiscal year, 30 days ago: $0.00 Next fiscal year, 7 days ago: $0.00 Next fiscal year, Now: $0.00 $0.00

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$0.04−$0.01
60 days ago −$0.09$0.00
30 days ago −$0.09$0.00
7 days ago −$0.09$0.00
Now −$0.09$0.00

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.02 −$0.12 −500.0%
Mar 2026 −$0.04 $0.04 +212.0%
Dec 2025 −$0.01 −$0.06 −500.0%
Sept 2025 −$0.02 −$0.12 −500.0%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

4 analysts, Oct 2026
Buy4100%
Hold00%
Sell00%

Monthly trend

  1. Oct 202644
  2. Sep 202644
  3. Aug 202644

Counts of recommendations published by analysts covering Strata Critical Medical, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
6.5%
of tradable shares
Days to cover
5.63
at average volume
Short interest, 1 month
+4%
to October 15, 2026
Held by institutions
71%
of shares
Held by insiders
14.3%
of shares
Employees
327
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Recent prices are available. Older price history and the statistics that need it are being loaded in the background.

What moved the share price

Last 12 months −14.9%

$5.03 on October 31, 2025 to $4.28

ThenNowEffect
Revenue (last 12 months) $154m $256m +66.8%
P/S multiple 2.6x 1.4x −44.8%
Share count 79m 86m −7.5%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

Last 3 years +78.3%

$2.40 on November 3, 2023 to $4.28

ThenNowEffect
Revenue (last 12 months) $190m $256m +34.6%
P/S multiple 0.9x 1.4x +62.0%
Share count 70m 86m −18.3%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
SRTA−20%−60%−1%+20%+13%−11%
Industry peers (median)−1%−25%+8%−6%−9%+15%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
SRTA50%50%58%42%42%36%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
SRTA−63%−67%−58%−39%−49%−34%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 5, 2019: 89% from February 16, 2021 to November 1, 2023. Getting back needed a 794% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$4.03 – $6.47
From 52-week high
−33.8%
vs 50-day average
−15.5%
vs 200-day average
−15.9%
Volatility (1 year)
55%
Beta vs S&P 500
2.09

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
7 up, 4 down
typical move ±12.5%
After a week
9 up, 2 down
typical move ±10.0%
After a month
5 up, 6 down
typical move ±10.7%
Results releasedNext dayS&P 500 next day5 days21 days
August 4, 2026 +5.4% +1.6% +8.6% −2.9%
May 6, 2026 +10.8% +1.1% +12.7% +20.1%
March 3, 2026 +8.9% −0.2% +3.6% −6.9%
November 10, 2025 +13.8% +1.8% +0.5% +4.3%
August 5, 2025 −12.6% +0.3% +1.6% −5.6%
May 12, 2025 +18.2% +4.0% +17.5% +41.4%
March 13, 2025 +11.0% +0.7% +6.4% −4.9%
November 12, 2024 −4.4% −0.3% −14.1% +8.9%
August 7, 2024 +17.3% +1.6% +4.7% +2.9%
May 7, 2024 −3.3% +0.1% +1.7% −16.0%
March 12, 2024 −32.1% +0.9% −38.6% −3.5%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Revenue (TTM) Strata Critical Medical, Inc.
$150M $200M $250M $300M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $215.8M Revenue (TTM), FY23 Q4: $225.2M Revenue (TTM), FY24 Q1: $231.4M Revenue (TTM), FY24 Q2: $238.4M Revenue (TTM), FY24 Q3: $203M Revenue (TTM), FY24 Q4: $191.9M Revenue (TTM), FY25 Q1: $176.3M Revenue (TTM), FY25 Q2: $153.5M Revenue (TTM), FY25 Q3: $166.7M Revenue (TTM), FY25 Q4: $197.1M Revenue (TTM), FY26 Q1: $228.6M Revenue (TTM), FY26 Q2: $256M $256M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $215.8M
FY23 Q4 $225.2M
FY24 Q1 $231.4M
FY24 Q2 $238.4M
FY24 Q3 $203M
FY24 Q4 $191.9M
FY25 Q1 $176.3M
FY25 Q2 $153.5M
FY25 Q3 $166.7M
FY25 Q4 $197.1M
FY26 Q1 $228.6M
FY26 Q2 $256M
Revenue growth, TTM YoY Strata Critical Medical, Inc.
-50% 0% 50% 100% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: 62.8% Revenue growth, TTM YoY, FY23 Q4: 54.1% Revenue growth, TTM YoY, FY24 Q1: 40.5% Revenue growth, TTM YoY, FY24 Q2: 25.4% Revenue growth, TTM YoY, FY24 Q3: -5.9% Revenue growth, TTM YoY, FY24 Q4: -14.8% Revenue growth, TTM YoY, FY25 Q1: -23.8% Revenue growth, TTM YoY, FY25 Q2: -35.6% Revenue growth, TTM YoY, FY25 Q3: -17.9% Revenue growth, TTM YoY, FY25 Q4: 2.7% Revenue growth, TTM YoY, FY26 Q1: 29.6% Revenue growth, TTM YoY, FY26 Q2: 66.8% 66.8%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 62.8%
FY23 Q4 54.1%
FY24 Q1 40.5%
FY24 Q2 25.4%
FY24 Q3 -5.9%
FY24 Q4 -14.8%
FY25 Q1 -23.8%
FY25 Q2 -35.6%
FY25 Q3 -17.9%
FY25 Q4 2.7%
FY26 Q1 29.6%
FY26 Q2 66.8%
Operating margin (TTM) Strata Critical Medical, Inc.
-40% -30% -20% -10% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -24.2% Operating margin (TTM), FY23 Q4: -30.3% Operating margin (TTM), FY24 Q1: -28.2% Operating margin (TTM), FY24 Q2: -27.3% Operating margin (TTM), FY24 Q3: -31.9% Operating margin (TTM), FY24 Q4: -18.2% Operating margin (TTM), FY25 Q1: -17.5% Operating margin (TTM), FY25 Q2: -15.2% Operating margin (TTM), FY25 Q3: -13.1% Operating margin (TTM), FY25 Q4: -11.3% Operating margin (TTM), FY26 Q1: -8.6% Operating margin (TTM), FY26 Q2: -8.0% -8.0%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -24.2%
FY23 Q4 -30.3%
FY24 Q1 -28.2%
FY24 Q2 -27.3%
FY24 Q3 -31.9%
FY24 Q4 -18.2%
FY25 Q1 -17.5%
FY25 Q2 -15.2%
FY25 Q3 -13.1%
FY25 Q4 -11.3%
FY26 Q1 -8.6%
FY26 Q2 -8.0%
FCF margin (TTM) Strata Critical Medical, Inc.
-40% -30% -20% -10% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: -15.9% FCF margin (TTM), FY23 Q4: -15.3% FCF margin (TTM), FY24 Q1: -14.5% FCF margin (TTM), FY24 Q2: -13.9% FCF margin (TTM), FY24 Q3: -18.7% FCF margin (TTM), FY24 Q4: -18.5% FCF margin (TTM), FY25 Q1: -12.6% FCF margin (TTM), FY25 Q2: -12.7% FCF margin (TTM), FY25 Q3: -33.8% FCF margin (TTM), FY25 Q4: -30.4% FCF margin (TTM), FY26 Q1: -25.4% FCF margin (TTM), FY26 Q2: -19.3% -19.3%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 -15.9%
FY23 Q4 -15.3%
FY24 Q1 -14.5%
FY24 Q2 -13.9%
FY24 Q3 -18.7%
FY24 Q4 -18.5%
FY25 Q1 -12.6%
FY25 Q2 -12.7%
FY25 Q3 -33.8%
FY25 Q4 -30.4%
FY26 Q1 -25.4%
FY26 Q2 -19.3%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q, 10-QT. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2019 Sept 2019 2020 Sept 2020 2021 Sept 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 31 23 51 146 225 147 197 256
Gross profit 5 2 11 22 42 30 41 53
EBITDA −11 −10 −23 −48 −61 −17 −14 −11
Operating income −12 −10 −24 −54 −68 −23 −22 −20
Net income −11 −10 −40 −27 −56 −27 41 40
Diluted EPS −$0.43 −$0.40 −$0.93 −$0.38 −$0.76 −$0.35 $0.50 $0.47
Growth (year on year)
Revenue — −24.9% +115.6% +189.2% +54.1% −34.8% +34.3% +66.8%
Margins
Gross margin 15.1% 9.9% 20.8% 15.2% 18.7% 20.2% 20.9% 20.6%
EBITDA margin −35.5% −42.0% −46.5% −32.7% −27.1% −11.3% −7.2% −4.4%
Operating margin −37.0% −44.2% −47.7% −36.6% −30.3% −15.3% −11.3% −8.0%
Net margin −34.7% −43.4% −79.3% −18.7% −24.9% −18.6% 21.0% 15.7%
Free-cash-flow margin −35.0% −47.8% −31.5% −25.9% −15.3% −22.7% −29.7% −18.9%
Cash flow
Cash from operations −10 −11 −16 −37 −32 −3 −49 −36
Capital spending 1 0 0 1 2 31 10 12
Free cash flow −11 −11 −16 −38 −34 −33 −59 −48
Stock-based pay 0 0 10 8 13 20 18 17
Free cash flow after stock pay −11 −12 −26 −46 −47 −53 −76 −65
Balance sheet
Cash — — — 41 28 18 31 16
Total debt 0 1 0 0 0 0 0 0
Net debt (negative = net cash) — — — −41 −28 −18 −31 −16
Diluted shares 25m 25m 43m 71m 74m 77m 82m 86m
Returned to shareholders
Buybacks — — — — 0 0 0 —
Total returned — — — — 0 0 0 —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 2 checks passed · June 30, 2026
What it owns · $333m
Short-term assets $121mLonger-term assets $212m
What it owes, and who funded it · $333m
Short-term liabilities $46mLonger-term liabilities $8mShareholders' equity $279m
  • Short-term assets cover short-term liabilities $121m of assets due within a year against $46m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $121m short-term assets against $8m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Strata Critical Medical, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Buybacks, last 3 fiscal years
$244,000
Diluted share count
+8.1%
year over year
R&D spending
2.6%
of revenue
Days sales outstanding
62 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in health care services
Last 12 months unless stated SRTA DLHC DCGO VMD SBC PETS Median
Revenue, last 12 months $256m $254m $295m $302m $175m $169m $1.1bn
Revenue growth, last 12 months 66.8% −29.5% −32.4% 25.2% −6.9% −20.3% 7.4%
Revenue growth, 3-year average 10.4% −9.5% −13.3% 24.5% — −13.0% 11.2%
Revenue growth, latest quarter 60.7% −46.9% −8.7% 23.9% 13.4% −19.9% 8.6%
Gross margin 20.6% 24.3% — 57.5% 71.9% 27.9% 27.8%
Operating margin −8.0% −0.1% −62.2% 7.5% 37.3% −18.2% 2.0%
Operating margin, 3-year average −16.8% 3.5% −20.8% 7.9% 37.3% −12.6% 2.0%
Net margin 15.7% −8.5% −65.3% 4.8% 28.0% −17.3% 1.2%
Cash from operations / revenue −14.1% 5.5% −7.7% 20.2% 35.9% −14.1% 5.8%
Free-cash-flow margin −19.3% 5.5% −8.8% 9.7% 35.3% −16.4% 4.2%
Free-cash-flow margin, 3-year average −15.3% 6.6% 1.4% 4.1% — −7.3% 3.5%
Stock pay / revenue 6.6% 0.5% 4.6% 3.0% — 0.6% 1.1%
Change in share count 8.1% 2.2% −7.1% −1.6% 1.4% 2.9% 0.4%

Median of all 42 companies we cover in health care services. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Where the revenue comes from

Fiscal year to December 31, 2025
Segments
Line of business Revenue Share YoY
Logistics $177M 89.7% ▲ 20.4%
Clinical $20.3M 10.3% —

From Strata Critical Medical, Inc.'s 10-K filed March 3, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$294M
Institutions reporting
139
Shares held vs prior quarter
▼ 0.1%
Positions opened / closed
30 / 16

Top buyers and sellers, Q2 2026: 81 institutions bought and 54 sold ; the biggest buyer was First Eagle Investment Management, LLC (+2.4M shares) and the biggest seller ARK Investment Management LLC (−4.7M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Third Point LLC $26.4M 5.0M 9.0% 0.0%
Northern Right Capital Management, L.P. $25.8M 4.9M 8.8% ▲ 19.6%
Blackrock, Inc. $25.5M 4.8M 8.7% ▲ 5.9%
First Eagle Investment Management, LLC $24.4M 4.6M 8.3% ▲ 104.3%
Royce & Associates LP $16.5M 3.1M 5.6% ▲ 11.2%
Vanguard Capital Management LLC $15.2M 2.9M 5.2% ▲ 0.4%
Awm Investment Company, Inc. $14.9M 2.8M 5.1% 0.0%
ARK Investment Management LLC $14.4M 2.7M 4.9% ▼ 63.4%
Pillsbury Lake Capital LLC $11.4M 2.2M 3.9% ▼ 16.6%
Geode Capital Management, LLC $9.3M 1.8M 3.2% ▲ 3.3%
Dimensional Fund Advisors LP $9.2M 1.7M 3.1% ▲ 7.5%
State Street Corp $8M 1.5M 2.7% ▲ 13.2%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Strata Critical Medical, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $97,840 2 trades by 2 insiders, last 12 months Insider sales History → $927,347 10 trades by 5 insiders · 41% under pre-set plans
Net ▼ $829,507 net selling
Insider Date Trade Shares Price Value
Love Reginald Director August 10, 2026 Sell 5,091 $5.75 $29,273
Wunsch Scott M CEO, Logistics June 8, 2026 Sell 5,550 $5.87 $32,578
Tomkiel Melissa M. Co-CEO and General Counsel June 8, 2026 Sell 29,730 $5.87 $174,515
Cohen Amir Chief Accounting Officer June 8, 2026 Sell 4,655 $5.87 $27,325
Heyburn William A. Co-CEO and CFO June 8, 2026 Sell 31,671 $5.87 $185,909
Cohen Amir Chief Accounting Officer May 22, 2026 Sell pre-set plan 40,575 $5.91 $239,798
Cohen Amir Chief Accounting Officer May 21, 2026 Sell pre-set plan 10,300 $5.79 $59,637
Cohen Amir Chief Accounting Officer May 11, 2026 Sell pre-set plan 14,306 $5.79 $82,832
Heyburn William A. Co-CEO and CFO December 9, 2025 Buy 17,000 $4.47 $75,990
Lauck Andrew Director December 5, 2025 Buy 5,000 $4.37 $21,850
Love Reginald Director November 20, 2025 Sell 11,000 $4.37 $48,070
Love Reginald Director November 19, 2025 Sell 11,000 $4.31 $47,410

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around February 1, 2027 estimated from the company's past filing pattern, not announced

  • November 3, 2026
  • August 4, 2026
  • May 6, 2026
  • March 3, 2026
  • November 10, 2025
  • August 5, 2025

Recent SEC filings

Data status

When each part of this page on Strata Critical Medical, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Strata Critical Medical, Inc. in brief

What does Strata Critical Medical, Inc. do?
Strata Critical Medical, Inc. is a US-listed company in the health care services industry. Its financial year ends in December.
What is Strata Critical Medical, Inc.'s stock ticker?
Strata Critical Medical, Inc. trades under the ticker SRTA on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Strata Critical Medical, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Strata Critical Medical, Inc. reported revenue of $256M, 66.8% higher than a year earlier, according to its SEC filings.
What is Strata Critical Medical, Inc.'s free cash flow?
Strata Critical Medical, Inc.'s free-cash-flow margin is -19.3% of revenue over the trailing twelve months.
Who are Strata Critical Medical, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Third Point LLC, Northern Right Capital Management, L.P. and Blackrock, Inc. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Strata Critical Medical, Inc.'s market cap?
On November 2, 2026, Strata Critical Medical, Inc.'s market capitalisation was about $368M, with a price-to-earnings ratio of 9.1 and net debt of -$16.3M. Market figures come from third-party market data and may be delayed.
Who are Strata Critical Medical, Inc.'s competitors?
In our Health Care Services peer group, the companies closest to Strata Critical Medical, Inc. are DLH Holdings Corp., Docgo Inc., Viemed Healthcare, Inc., SBC Medical Group Holdings Inc and Petmed Express Inc. The side-by-side comparison below sets their revenue, margins and growth against Strata Critical Medical, Inc.'s.
Are insiders buying or selling Strata Critical Medical, Inc. stock?
Over the last 12 months, Strata Critical Medical, Inc.'s directors and officers reported 2 open-market purchases and 10 sales on Form 4. The insider trading page charts every trade.
When is Strata Critical Medical, Inc.'s next earnings date?
Around November 3, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Strata Critical Medical, Inc. announces its own schedule.